Corporate Member Merck - NEW Formulation

Corporate Member Merck - NEW Formulation

EMENDâ„¢ (fosaprepitant)
July, 2017

FDA approval for a new formulation of EMEND for injection that has a lower concentration of edetate disodium (EDTA), an inactive ingredient.  This new formulation (5.4 mg EDTA, NDC 0006-3061-00) will replace the existing formulation (18.8 mg EDTA, NDC 0006-3941-32).  The purpose of this formulation change is to support ongoing regulatory activities for EMEND.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members